Home Vision Monitoring Using the ForeseeHome Device Following Treatment of Neovascular Age Related Macular Degeneration (CNV)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01334294
Recruitment Status : Completed
First Posted : April 13, 2011
Last Update Posted : October 3, 2014
Information provided by (Responsible Party):
Notal Vision Ltd

Brief Summary:
ForeseeHome, an FDA-approved home device, was specifically designed for unsupervised Preferential-Hyperacuity-Perimeter (PHP) testing of Age Related Macular Degeneration (AMD) patients at home by characterizing central and paracentral metamorphopsia . The purpose of the current study is to evaluate if, in post-treatment patients, PHP parameters as measured with the ForeseeHome are in agreement with clinical decisions and retinal characteristics as measured with optical coherence tomography (OCT).

Condition or disease Intervention/treatment
Age Related Macular Degeneration Choroidal Neovascularization Device: ForeseeHome

Study Type : Observational
Actual Enrollment : 120 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Home Vision Monitoring Using the ForeseeHome Device Following Treatment of Neovascular AMD
Study Start Date : April 2011
Primary Completion Date : December 2013
Study Completion Date : March 2014

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Group/Cohort Intervention/treatment
1. Received therapy for CNV Device: ForeseeHome
The ForeseeHomeTM device, was designed to identify central and paracentral irregularities (vision abnormalities) in the visual field, most commonly associated with exudative macular degeneration.

Primary Outcome Measures :
  1. Assess the accuracy of the ForeseeHome to detect reactivation of CNV following successful treatment with Anti-VEGF [ Time Frame: 1 year ]

Secondary Outcome Measures :
  1. Evaluate the correlation between PHP measures and OCT measures [ Time Frame: 1 year ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   55 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population

Inclusion Criteria:

  1. Received intravitreal antiangiogenic therapy for CNV in the study eye (SE), within 2-12 months prior to the study
  2. Last diagnosis was, and current diagnosis is, no CNV activity in SE eye
  3. Current plan in SE is clinical examination as standard care but at intervals of not more than 8 weeks.
  4. Visual acuity of 20/80 or better in SE
  5. Are capable and agree to sign a consent form and participate in the study
  6. Age > 55 year of age
  7. Are able to use a standard computer mouse correctly and without assistance
  8. Have a working telephone landline at the main residence (cellular communication maybe available for the study, and then eliminate this requirement)
  9. Clear view of the macular area on fundus photography
  10. Are willing to give their name and contact information to Notal Vision, supplier of the device, so that the company can provide direct services if needed (e.g., assist in using the home device, report the frequency of usage, coordinate replacement of devices in case of a technical problems, etc.)
  11. Agree to be examined by an ophthalmologist if SE shows symptoms of changes during the study
  12. Have a US address and do not plan on traveling abroad during the study period
  13. Fluent in English
  14. Perform a reliable ForeseeHome test during the enrollment visit

Exclusion Criteria:

  1. Evidence of macular disease other than AMD or glaucoma in SE
  2. Presence of any significant media opacity that precludes a clear view of the macular area as identified in SE by biomicroscopy
  3. Any non-macular related ocular surgery performed within 3 months prior to study entry in SE
  4. Participant are not enrolled in another stuy that could affect the interval between clinical examinations, or the frequency of use of the ForeseeHome device

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01334294

United States, Florida
Retina Care specisalists
Palm Beach Gardens, Florida, United States
United States, Maryland
Elman retina group
Baltimore, Maryland, United States
United States, Missouri
Pepose Vision Institute
St. Louis, Missouri, United States
Sponsors and Collaborators
Notal Vision Ltd
Principal Investigator: Mark Michels, MD Retina care specialists

Responsible Party: Notal Vision Ltd Identifier: NCT01334294     History of Changes
Other Study ID Numbers: PT US 001.2
First Posted: April 13, 2011    Key Record Dates
Last Update Posted: October 3, 2014
Last Verified: October 2014

Keywords provided by Notal Vision Ltd:

Additional relevant MeSH terms:
Macular Degeneration
Neovascularization, Pathologic
Choroidal Neovascularization
Retinal Degeneration
Retinal Diseases
Eye Diseases
Pathologic Processes
Choroid Diseases
Uveal Diseases